Trial Profile

Pharmacokinetic study of rolapitant + midazolam in volunteers.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rolapitant (Primary) ; Midazolam
Indications Chemotherapy-induced nausea and vomiting
Focus Pharmacokinetics

Most Recent Events

13 Nov 2018 Results of this and other two phase I studies published in the Journal of Clinical Pharmacology.
08 Jul 2013 New trial record
28 Jun 2013 Results presented at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) International Symposium, according to a TESARO media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com